L. Hansen

Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.

A. Gruhler, J. Clausen, H. H. Petersen, 2012, Blood.

Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide.

T. Nichols, Henrik Østergaard, T. N. Krogh, 2011, Blood.

Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration.

R. V. Overgaard, L. C. Petersen, H. Agersø, 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease

S. Vergo, C. Haase, B. Sondergaard, 2018, Gastroenterology research and practice.

Activation peptides prolong the murine plasma half-life of human factor VII.

E. Persson, L. Johansson, H. Pelzer, 2011, Blood.

Investigating clearance mechanisms for recombinant activated factor VII in a perfused liver model

C. Behrens, M. S. Christensen, N. K. Klausen, 2010, Thrombosis and Haemostasis.

Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz-type protease inhibitor 2 domain of Tissue Factor Pathway Inhibitor.

K. Almholt, J. Clausen, B. Lauritzen, 2014, Thrombosis research.

Hyperglycosylation prolongs the circulation of coagulation factor IX

J. Bjelke, G. Bolt, D. Karpf, 2012, Journal of thrombosis and haemostasis : JTH.

Modulating the Antithrombin-Mediated in Vivo Clearance of Coagulation Factor VIIa

O. Olsen, Henrik Østergaard, H. Stennicke, 2014 .

Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide.

T. Nichols, Henrik Østergaard, F. Møller, 2011, Blood.